In a study in the American Journal of Ophthalmology 2009;147:45-50, eyes with ta mean pretreatment IOP of 31.3 had a rapid and significant decrease of IOP by 9.5mmHg wihtin 1 week. by 4 weeks th emean IOP decreased by 12.7mmHg. These reductions were maintained at 6 months and 12 months. No adverse side effects were noted.
This was a small pilot study that lacked control data, howerver anecortave acetate may be a promising contender for IOP reduction in eyes with glaucoma.